Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Gilead Sciences (GILD +5.3%) pops after saying it plans to initiate a Phase III trial to evaluate a combination of sofosbuvir and ledipasvir in patients with hepatitis C. Phase II results suggest "once-daily oral therapy with [the combo] may have the potential to cure most genotype 1 HCV infected patients with a remarkably short treatment duration," says Dr. Eric Lawitz, the study's principal investigator. Some have suggested a combination of sofosbuvir and BMY's daclatasvir is preferable, as both are active in genotype 3 HCV whereas ledipasvir may only be effective against genotype 1. (Related: I, II, III[View news story]
    Gilead needs to start up another late stage study with BMY's
    Daclatasvar which is superior in combination with sofosbufir for genotype 2 and 3.
    I surmise that it's distasteful for gilead to work with BMY and split the profits
    for the sake of medicine instead of developing an inferior product just to maximize their own profits.
    May 2, 2013. 11:03 AM | Likes Like |Link to Comment
  • Bank of America (BAC) has won federal judge's approval for a $2.43B settlement with investors who said the lender hid crucial information when it bought Merrill Lynch in a $50B all-stock deal in September 2008. The settlement, which is among the largest stemming from the global financial crisis, culminated from what the judge referred to as "extraordinarily hard-fought litigation." [View news story]
    The paperwork for the class action calls for more than 3 dollars per share before expenses
    Apr 8, 2013. 06:45 AM | Likes Like |Link to Comment